 This is a Phase 2a, partially-blind, randomized study drug assigned by chance and multiple-dose study to evaluate the activity and safety of telaprevir on HCV early viral kinetics in treatment-naive participants who are chronically infected with HCV Genotype 4. The study consists of 4 parts: Screening period 6-week; Investigational Treatment period consisting of 2-week treatment with telaprevir or telaprevirstandard treatment or placebo; Standard Treatment period consists of 46 or 48-week standard treatment; and Follow-up period 24-week. The activity of telaprevir will be evaluated by early viral kinetic parameters along with viral response and pharmacokinetic assessments during the investigational treatment phase. Participants safety will be monitored throughout the study. 